{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:22:20Z","timestamp":1793762540380,"version":"4.6.1"},"reference-count":96,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Transformation to aggressive lymphoma is a critical event in the clinical course of follicular lymphoma (FL) patients. Yet, it is a challenge to reliably predict transformation at the time of diagnosis. Understanding the risk of transformation would be useful for guiding and monitoring patients, as well as for evaluating novel treatment strategies that could potentially prevent transformation. Herein, we review the contribution of clinical, pathological, and genetic risk factors to transformation. Patients with multiple clinical high-risk factors are at elevated risk of transformation but we are currently lacking a prognostic index that would specifically address transformation rather than disease progression or overall survival. From the biological standpoint, multiple studies have correlated individual biomarkers with transformation. However, accurate prediction of this event is currently hampered by our limited knowledge of the evolutionary pathways leading to transformation, as well as the scarcity of comprehensive, large-scale studies that assess both the genomic landscape of alterations within tumor cells and the composition of the microenvironment. Liquid biopsies hold great promise for achieving precision medicine. Indeed, mutations detected within circulating tumor DNA may be a better reflection of the inherent intratumoral heterogeneity than the biopsy of a single site. Last, we will assess whether evidence exists in the literature that transformation might be prevented altogether, based on the choice of therapy for FL.<\/jats:p>","DOI":"10.1182\/blood-2017-03-691345","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T21:10:34Z","timestamp":1492117834000},"page":"258-266","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["Can histologic transformation of follicular lymphoma be predicted and prevented?"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":false,"given":"Robert","family":"Kridel","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2610-5690","authenticated-orcid":false,"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;"},{"name":"Department of Pathology and Laboratory Medicine, BC Cancer Agency, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111906314632400_B1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2019111906314632400_B2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111906314632400_B3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"suppl 5","key":"2019111906314632400_B4","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111906314632400_B5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111906314632400_B6","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3109\/10428194.2014.885513","article-title":"Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis","volume":"55","author":"Mozessohn","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2019111906314632400_B7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111906314632400_B8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111906314632400_B9","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111906314632400_B10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111906314632400_B11","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111906314632400_B12","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111906314632400_B13","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111906314632400_B14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111906314632400_B15","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA Trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111906314632400_B16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"18","key":"2019111906314632400_B17","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111906314632400_B18","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2019111906314632400_B19","first-page":"1790","article-title":"Predicting malignancy grade with PET in non-Hodgkin\u2019s lymphoma","volume":"36","author":"Rodriguez","year":"1995","journal-title":"J Nucl Med"},{"issue":"1","key":"2019111906314632400_B20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"2019111906314632400_B21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111906314632400_B22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.114.149625","article-title":"18F-FDG or 3\u2032-deoxy-3\u2032-18F-fluorothymidine to detect transformation of follicular lymphoma","volume":"56","author":"Wondergem","year":"2015","journal-title":"J Nucl Med"},{"issue":"3","key":"2019111906314632400_B23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2019111906314632400_B24","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"2","key":"2019111906314632400_B25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2019111906314632400_B26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Reports"},{"issue":"8","key":"2019111906314632400_B27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"issue":"7","key":"2019111906314632400_B28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"issue":"3","key":"2019111906314632400_B29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","article-title":"MYC rearrangements in histologically progressed follicular lymphomas","volume":"80","author":"Yano","year":"1992","journal-title":"Blood"},{"issue":"3","key":"2019111906314632400_B30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/10428190310001593120","article-title":"The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases","volume":"45","author":"Au","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019111906314632400_B31","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1073\/pnas.132253599","article-title":"Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes","volume":"99","author":"Lossos","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111906314632400_B32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111906314632400_B33","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.leu.2404696","article-title":"Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma","volume":"21","author":"Fitzgibbon","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2019111906314632400_B34","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","article-title":"Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma","volume":"91","author":"Elenitoba-Johnson","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111906314632400_B35","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984","article-title":"p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin\u2019s lymphomas","volume":"91","author":"Pinyol","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2019111906314632400_B36","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111906314632400_B37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2019111906314632400_B38","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111906314632400_B39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111906314632400_B40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111906314632400_B41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1078\/0344-0338-00421","article-title":"Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein","volume":"199","author":"Shiozawa","year":"2003","journal-title":"Pathol Res Pract"},{"issue":"1","key":"2019111906314632400_B42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111906314632400_B43","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111906314632400_B44","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111906314632400_B45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111906314632400_B46","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3324\/haematol.2009.021766","article-title":"Vascularization predicts overall survival and risk of transformation in follicular lymphoma","volume":"95","author":"Farinha","year":"2010","journal-title":"Haematologica"},{"issue":"15","key":"2019111906314632400_B47","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood-2009-02-202465","article-title":"A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients","volume":"114","author":"Gentles","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111906314632400_B48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2013-07-512392","article-title":"Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma","volume":"123","author":"Brodtkorb","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111906314632400_B49","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2010-10-315382","article-title":"SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma","volume":"117","author":"Wrench","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111906314632400_B50","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2011-06-362921","article-title":"SNP rs6457327 is a predictor for overall survival in follicular lymphoma as well as survival after transformation","volume":"118","author":"Berglund","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111906314632400_B51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2008-02-140616","article-title":"Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances","volume":"113","author":"Cheung","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111906314632400_B52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM198701083160204","article-title":"Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer","volume":"316","author":"Yunis","year":"1987","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111906314632400_B53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V84.4.1043.1043","article-title":"Prognostic value of chromosomal abnormalities in follicular lymphoma","volume":"84","author":"Tilly","year":"1994","journal-title":"Blood"},{"issue":"9","key":"2019111906314632400_B54","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood-2010-03-272278","article-title":"Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones","volume":"116","author":"Eide","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111906314632400_B55","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O\u2019Shea","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111906314632400_B56","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2002-08-2482","article-title":"BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma","volume":"102","author":"Akasaka","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111906314632400_B57","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"364","key":"2019111906314632400_B58","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"2019111906314632400_B59","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"11","key":"2019111906314632400_B60","first-page":"4649","article-title":"BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH\/BCL2","volume":"29","author":"Gollub","year":"2009","journal-title":"Anticancer Res"},{"issue":"7","key":"2019111906314632400_B61","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2006-09-045989","article-title":"CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features","volume":"109","author":"Karube","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111906314632400_B62","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.humpath.2014.06.019","article-title":"Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis","volume":"45","author":"Xerri","year":"2014","journal-title":"Hum Pathol"},{"issue":"6","key":"2019111906314632400_B63","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdp460","article-title":"Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study","volume":"21","author":"Sweetenham","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111906314632400_B64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111906314632400_B65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"issue":"10","key":"2019111906314632400_B66","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"2019111906314632400_B67","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111906314632400_B68","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"16","key":"2019111906314632400_B69","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-07-0456","article-title":"Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis","volume":"13","author":"Ross","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111906314632400_B70","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111906314632400_B71","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10428190701836845","article-title":"C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator?","volume":"49","author":"Christie","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111906314632400_B72","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V92.9.3018.421k52_3018_3024","article-title":"Somatic Fas mutations in non-Hodgkin\u2019s lymphoma: association with extranodal disease and autoimmunity","volume":"92","author":"Gr\u00f8nbaek","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111906314632400_B73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/1042819031000090228","article-title":"Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma","volume":"44","author":"Do","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111906314632400_B74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ajh.24701","article-title":"BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab","volume":"92","author":"Huet","year":"2017","journal-title":"Am J Hematol"},{"issue":"4260","key":"2019111906314632400_B75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"15","key":"2019111906314632400_B76","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2008-08-174839","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone","volume":"113","author":"Carlotti","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111906314632400_B77","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111906314632400_B78","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"issue":"4","key":"2019111906314632400_B79","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.1994.tb04828.x","article-title":"Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia","volume":"86","author":"Vasioukhin","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111906314632400_B80","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"2019111906314632400_B81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study [published correction appears in Lancet Oncol. 2015;16(5):e199]","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"24","key":"2019111906314632400_B82","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111906314632400_B83","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111906314632400_B84","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"de Jong","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111906314632400_B85","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2013.095257","article-title":"The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium","volume":"99","author":"Sander","year":"2014","journal-title":"Haematologica"},{"issue":"283","key":"2019111906314632400_B86","doi-asserted-by":"crossref","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019111906314632400_B87","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/j.seminoncol.2015.09.026","article-title":"The personalization of therapy: molecular profiling technologies and their application","volume":"42","author":"Zeron-Medina","year":"2015","journal-title":"Semin Oncol"},{"issue":"1","key":"2019111906314632400_B88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-med-102115-021556","article-title":"Next-generation sequencing and result interpretation in clinical oncology: challenges of personalized cancer therapy","volume":"68","author":"Khotskaya","year":"2017","journal-title":"Annu Rev Med"},{"issue":"23","key":"2019111906314632400_B89","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111906314632400_B90","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9383","key":"2019111906314632400_B91","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"2019111906314632400_B92","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111906314632400_B93","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00277-015-2303-5","article-title":"Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis","volume":"94","author":"Lerch","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"2019111906314632400_B94","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2019111906314632400_B95","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111906314632400_B96","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/3\/258\/1404509\/blood691345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/3\/258\/1404509\/blood691345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T06:34:31Z","timestamp":1574145271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/3\/258\/36907\/Can-histologic-transformation-of-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-03-691345","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]}}}